Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
MPM BioVentures 2014, L.P. and related entities sold a total of 195,666 shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) common stock in three separate transactions, amassing approximately $179,551 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback